Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach

Abstract

5-Fluorodeoxyuridine was administered to 185 patients randomized to the treated group following gastric resection for carcinoma of the stomach. Two hundred twelve patients were randomized to control groups. There are no significant differences in operative mortality, complications, or 3-year survival rates.